

Why accountability and transparency matter for access to medicines

2018 Access to Medicine Index

DANNY EDWARDS, MYRIAM DIALLO

10 July 2019, Combatting Corruption and Promoting Equity in the Health
Sector, UC San Diego

Overview

- The Access to Medicine Foundation
- Compliance, anti-corruption and access to medicine
- The Access to Medicine Index
- 2018 findings on compliance and anti-corruption

About the Foundation

- Stimulates and incentivises pharmaceutical companies to improve access to medicine
- Independent non-profit organisation, no funding from the pharmaceutical industry
- Multi-stakeholder approach



Ministry of Foreign Affairs
of the Netherlands

BILL & MELINDA
GATES *foundation*



Ministry of Health, Welfare and Sport

Our model for change


Build consensus

on where pharmaceutical companies can and should be taking action to improve access to medicine.



Stimulate a race to do well

in key access-to-medicine areas, by creating competition on targets and topics.



Share best practices

identify and facilitate the wider application of best practices and new insights to drive change.




90 signatory investors: AUM in excess of USD 11 trillion

access to
medicine
FOUNDATION




Compliance, anti-corruption and access to medicine

WHO's Access to medicine framework (2004)



The medicines chain is a system inherently challenging to govern



Why do compliance and anti-corruption matter for access to medicine?

Corruption and misconduct in the health sector directly impact on global health outcomes in general, and on access to medicine in particular:

- *Up to USD 300 million of annual global health expenditure is lost in corruption*

Source: World Health Organization, The World Health Report (2010), p.61

- *Medicines account for 3 of the top 10 leading sources of inefficiency in health systems – corruption being a leading source of inefficiency*

Source: Chisholm D, Evans DB. Improving health system efficiency as a means of moving towards universal coverage. World Health Organization (2010)

Why do compliance and anti-corruption matter for access to medicine? (cont.)


- Traditionally, focus for access to medicine has been on pricing, infrastructure, IP rights
- Growing attention on consequences of corruption and misconduct as a further barrier to access to medicine, especially in LMICs:
 - Unavailability of medicines in public sector due to money diversion
 - Impact on the poor for purchasing expensive medicines from private sector

2018 Access to Medicine Index

What we measure

In-depth reporting, in pdf and online


access to
medicine
FOUNDATION



3 KEY FINDINGS

6 LEADING GRAPHICS

7 TECHNICAL AREAS



20 DETAILED COMPANY REPORT CARDS

45 BEST AND INNOVATIVE PRACTICES

Scopes of analysis

COMPANY SCOPE

20 companies

Selected based on a combination of market capitalisation and relevance of portfolio for access to medicine.

GEOGRAPHIC SCOPE

106 low and middle-income countries

- 31 low-income countries
- 52 lower-middle-income countries
- 23 upper-middle-income countries

DISEASE SCOPE

77 diseases, conditions and pathogens


- 21 communicable diseases
- 14 non-communicable diseases
- 20 neglected tropical diseases
- 10 maternal & neonatal health conditions
- 12 priority pathogens

PRODUCT TYPE SCOPE

8 types


Medicines, microbicides, preventive vaccines, therapeutic vaccines, vector control products, platform technologies, diagnostics, contraceptive methods and devices.

Analytical Framework




2018 Access to Medicine Index 2018 Rankings

2018 ACCESS TO MEDICINE INDEX – OVERALL RANKING



- General Access to Medicine Management
- Market Influence & Compliance
- Research & Development
- Pricing, Manufacturing & Distribution
- Patents & Licensing
- Capacity Building
- Product Donations

MARKET INFLUENCE & COMPLIANCE



2018 2016


● Commitments ● Transparency ● Performance ● Innovation

Market Influence & Compliance

9 companies demonstrate non-sales-related incentives



3 companies with comprehensive frameworks for compliance.



Market Influence & Compliance

Most compliance policies extend to third parties



5 companies ban political financial contributions



Methodology review for the next Access to Medicine Index

- Following the publication of the 10-Year Analysis in May 2019
- Review process for the next Access to Medicine Index
- External stakeholder consultation to refine the new analytical framework (indicator set and scopes) of pharmaceutical companies' responses to improve access to medicine

Thank you

DANNY EDWARDS, MYRIAM DIALLO
dedwards@accesstomedicinefoundation.org
mdiallo@accesstomedicinefoundation.org
www.accesstomedicinefoundation.org